These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Improved survival with MEK inhibition in BRAF-mutated melanoma. Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D; N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011 [TBL] [Abstract][Full Text] [Related]
29. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation. Kim G; McKee AE; Ning YM; Hazarika M; Theoret M; Johnson JR; Xu QC; Tang S; Sridhara R; Jiang X; He K; Roscoe D; McGuinn WD; Helms WS; Russell AM; Miksinski SP; Zirkelbach JF; Earp J; Liu Q; Ibrahim A; Justice R; Pazdur R Clin Cancer Res; 2014 Oct; 20(19):4994-5000. PubMed ID: 25096067 [TBL] [Abstract][Full Text] [Related]
30. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138 [TBL] [Abstract][Full Text] [Related]
32. The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use. da Rocha Dias S; Salmonson T; van Zwieten-Boot B; Jonsson B; Marchetti S; Schellens JH; Giuliani R; Pignatti F Eur J Cancer; 2013 May; 49(7):1654-61. PubMed ID: 23481513 [TBL] [Abstract][Full Text] [Related]